TEVA Teva Pharmaceutical Industries Ltd

  1. Stocks
  2. Healthcare
  3. NYSE: TEVA

Price (delayed)

$13.81

Market cap

$15.48B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.5

Enterprise value

$32.41B

Highlights
TEVA's net income has surged by 77% year-on-year and by 76% since the previous quarter
Teva Pharmaceutical Industries's EPS has surged by 77% YoY and by 76% QoQ
TEVA's quick ratio is up by 10% from the previous quarter but it is down by 5% YoY
Teva Pharmaceutical Industries's equity has increased by 8% QoQ but it has decreased by 3.8% YoY
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Website: http://www.tevapharm.com
Peers: NVS PFE MRK AZN

Key stats

What are the main financial stats of TEVA
Market
Shares outstanding
1.12B
Market cap
$15.48B
Enterprise value
$32.41B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.06
Price to sales (P/S)
0.98
EV/EBIT
66.01
EV/EBITDA
19.71
EV/Sales
2.05
Earnings
Revenue
$15.85B
EBIT
$491M
EBITDA
$1.64B
Free cash flow
$842M
Per share
EPS
-$0.5
Free cash flow per share
$0.75
Book value per share
$6.7
Revenue per share
$14.16
TBVPS
$18.69
Balance sheet
Total assets
$43.48B
Total liabilities
$35.35B
Debt
$20.15B
Equity
$7.51B
Working capital
$238M
Liquidity
Debt to equity
2.68
Current ratio
1.02
Quick ratio
0.54
Net debt/EBITDA
10.3
Margins
EBITDA margin
10.4%
Gross margin
48.3%
Net margin
-3.5%
Operating margin
2.7%
Efficiency
Return on assets
-1.3%
Return on equity
-7.6%
Return on invested capital
1.8%
Return on capital employed
1.6%
Return on sales
3.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TEVA stock price

How has the Teva Pharmaceutical Industries stock price performed over time
Intraday
4.23%
1 week
7.39%
1 month
-2.33%
1 year
68.21%
YTD
32.28%
QTD
-2.13%

Financial performance

How have Teva Pharmaceutical Industries's revenue and profit performed over time
Revenue
$15.85B
Gross profit
$7.65B
Operating income
$433M
Net income
-$559M
Gross margin
48.3%
Net margin
-3.5%
TEVA's operating income has soared by 135% from the previous quarter and by 120% YoY
The operating margin has soared by 133% QoQ and by 118% YoY
The net margin has surged by 79% year-on-year and by 77% since the previous quarter
TEVA's net income has surged by 77% year-on-year and by 76% since the previous quarter

Growth

What is Teva Pharmaceutical Industries's growth rate over time

Valuation

What is Teva Pharmaceutical Industries stock price valuation
P/E
N/A
P/B
2.06
P/S
0.98
EV/EBIT
66.01
EV/EBITDA
19.71
EV/Sales
2.05
Teva Pharmaceutical Industries's EPS has surged by 77% YoY and by 76% QoQ
TEVA's price to book (P/B) is 80% higher than its 5-year quarterly average of 1.1 and 41% higher than its last 4 quarters average of 1.4
Teva Pharmaceutical Industries's equity has increased by 8% QoQ but it has decreased by 3.8% YoY
The P/S is 57% above the 5-year quarterly average of 0.6 and 34% above the last 4 quarters average of 0.7
TEVA's revenue is up by 6% year-on-year and by 3.8% since the previous quarter

Efficiency

How efficient is Teva Pharmaceutical Industries business performance
The company's return on invested capital has surged by 143% QoQ and by 124% YoY
Teva Pharmaceutical Industries's return on sales has surged by 141% QoQ and by 122% YoY
Teva Pharmaceutical Industries's return on assets has surged by 76% YoY and by 75% QoQ
TEVA's ROE has soared by 76% from the previous quarter and by 73% YoY

Dividends

What is TEVA's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Recent dividends

Financial health

How did Teva Pharmaceutical Industries financials performed over time
The total assets is 23% greater than the total liabilities
TEVA's quick ratio is up by 10% from the previous quarter but it is down by 5% YoY
Teva Pharmaceutical Industries's current ratio has decreased by 2.9% YoY but it has increased by 2% QoQ
The debt is 168% greater than the equity
TEVA's debt to equity is down by 9% from the previous quarter and by 2.9% YoY
Teva Pharmaceutical Industries's equity has increased by 8% QoQ but it has decreased by 3.8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.